Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4144 - Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients


11 Sep 2017


Poster display session


Breast Cancer


Mariana Chavez Mac Gregor


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


M. Chavez Mac Gregor1, X. Lei2, H. Zhao2, S.H. Giordano1

Author affiliations

  • 1 Breast Medical Oncology, Health Services Research, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Health Services Research, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US


Abstract 4144


Adverse outcomes have been associated with delays in the administration of adjuvant chemotherapy among breast cancer patients. We evaluate the determinants and outcomes associated with delays in time to chemotherapy (TTC) in a large cohort of older breast cancer patients.


We used the NCI-Surveillance Epidemiology and End Results (SEER) and Texas Cancer Registry (TCR)-Medicare linked data bases to identify patients ≥66 years old diagnosed with localized or regional breast cancer between 2001-2011. All patients received chemotherapy within 9 months of surgery. Delayed TTC was defined as > 90 days. Multivariable logistic regression was used to identify predictors of treatment delay. A Cox Proportional Hazards model was fit to determine the association between treatment delay, overall survival (OS) and breast cancer specific survival (BCSS).


25,096 patients were included, of them 2,676 (10.7%) had a TTC >90 days. In multivariable analysis factors associated with delays in TTC were: recent year of diagnosis (2011 vs 2001 OR = 1.31; 95%CI 1.03-1.67), older age (76-80 vs 66-70 OR = 1.51; 95%CI 1.33-1.72), black race (OR = 1.35; 95%CI 1.14-1.58), having state buy-in (as an indicator of poverty) (OR = 1.27; 95%CI 1.1-1.47), comorbidities (Charlson score 1 OR = 1.23;95%CI 1.09-1.37; score 2 OR = 1.57; 95%CI 1.37-1.81), mastectomy (OR = 1.49; 95%CI 1.33-1.67), mastectomy with immediate reconstruction (OR = 1.85; 95%CI 1.37-2.48), Oncotype DX testing (OR = 1.68; 95%CI 1.4-2.02), mastectomy >30 days after the initial surgery (OR = 16.91; 95%CI 12.07-23.68), brachytherapy (OR = 4.11; 95%CI 3.17-5.34) and whole breast radiation prior to chemotherapy (OR = 31.9; 95%CI 28.05-36.49). After adjusting for potential confounders, patients with TTC >90 days had worse OS (HR = 1.37; 95%CI 1.27-1.48) and BCSS (HR = 1.34; 95%CI 1.19-1.51).


A delay in adjuvant chemotherapy administration >90 days is associated with adverse outcomes among older breast cancer patients. Determinants of delays were sociodemographic in nature, related to patient’s characteristics and to treatment received. Every effort should be made to identify vulnerable patients and to administer chemotherapy in a timely manner.

Clinical trial identification

Legal entity responsible for the study

The University of Texas MD Anderson Cancer Center


Susan G. Komen, CIPRIT


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.